Cargando…

Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status

This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two cohorts of BRCA1 and BRCA2 mutation carriers and controls. The first group was a prospective set of 665 male BRCA1/2 mutation carriers and controls (mean age 53 years), all healthy at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Killick, Emma, Tymrakiewicz, Malgorzata, Cieza-Borrella, Clara, Smith, Paula, Thompson, Deborah J., Pooley, Karen A., Easton, Doug F., Bancroft, Elizabeth, Page, Elizabeth, Leongamornlert, Daniel, Kote-Jarai, Zsofia, Eeles, Rosalind A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906069/ https://www.ncbi.nlm.nih.gov/pubmed/24489760 http://dx.doi.org/10.1371/journal.pone.0086659

Ejemplares similares

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls
por: Locke, Imogen, et al.
Publicado: (2007)

Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage
por: Kote-Jarai, Z, et al.
Publicado: (2008)

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
por: Kote-Jarai, Z, et al.
Publicado: (2011)

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants
por: Dias, Alexander, et al.
Publicado: (2023)

Corrigendum to “Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study” [Eur Urol 2014;66:489–99]
por: Bancroft, Elizabeth K., et al.
Publicado: (2015)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT
por: Ahmed, Mahbubl, et al.
Publicado: (2019)

LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations
por: Dadaev, Tokhir, et al.
Publicado: (2016)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease
por: Mijuskovic, Martina, et al.
Publicado: (2018)

Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease
por: Mijuskovic, Martina, et al.
Publicado: (2019)

Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
por: Eeles, Rosalind A
Publicado: (2000)

Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups
por: McHugh, Jana, et al.
Publicado: (2021)

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
por: Kadouri, L, et al.
Publicado: (2001)

Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease
por: Saunders, Edward J., et al.
Publicado: (2021)

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
por: Bancroft, Elizabeth K., et al.
Publicado: (2018)

Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
por: Kadouri, L, et al.
Publicado: (2008)

Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel
por: Leongamornlert, Daniel A., et al.
Publicado: (2019)

Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers
por: Kote-Jarai, Z, et al.
Publicado: (2006)

Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives
por: Ardern-Jones, Audrey, et al.
Publicado: (2010)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk
por: deSouza, Nandita M., et al.
Publicado: (2014)

BRCA2 Haploinsufficiency in Telomere Maintenance
por: Gunnarsdottir, Soffía R., et al.
Publicado: (2021)

Prostate Cancer Risks for Male BRCA1 [Image: see text] and BRCA2 Mutation Carriers: A Prospective Cohort Study()
por: Nyberg, Tommy, et al.
Publicado: (2020)

BRCA1 in the DNA damage response and at telomeres
por: Rosen, Eliot M.
Publicado: (2013)

A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk
por: Pooley, Karen A., et al.
Publicado: (2013)

Prostate Cancer Risk by BRCA2 Genomic Regions
por: Nyberg, Tommy, et al.
Publicado: (2020)

Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer
por: Moynihan, C., et al.
Publicado: (2017)

Mutation analysis of the MSMB gene in familial prostate cancer
por: Kote-Jarai, Z, et al.
Publicado: (2010)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic"
por: Ardern-Jones, Audrey, et al.
Publicado: (2004)

The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine
por: Whitaker, Hayley C., et al.
Publicado: (2010)

An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
por: Chenevix-Trench, Georgia, et al.
Publicado: (2007)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

Dynamic interaction of BRCA2 with telomeric G-quadruplexes underlies telomere replication homeostasis
por: Lee, Junyeop, et al.
Publicado: (2022)

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men
por: Killick, Emma, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_412gguc7oser9jg9bfk7a7qd8i